{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Diagnosis&page=6",
    "query": {
      "condition": "Schizophrenia Diagnosis",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1681,
    "total_pages": 169,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Diagnosis&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Diagnosis&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T11:30:20.156Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00594256",
      "title": "Sodium Oxybate in Schizophrenia With Insomnia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Insomnia Related to Schizophrenia (307.42)"
      ],
      "interventions": [
        {
          "name": "Sodium Oxybate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nathan Kline Institute for Psychiatric Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-05",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 1,
      "location_summary": "Orangeburg, New York",
      "locations": [
        {
          "city": "Orangeburg",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594256"
    },
    {
      "nct_id": "NCT03527186",
      "title": "Comparative Bioavailability of Risperidone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone ISM® 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rovi Pharmaceuticals Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 81,
      "start_date": "2018-07-09",
      "completion_date": "2019-04-06",
      "has_results": false,
      "last_update_posted_date": "2021-12-16",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 2,
      "location_summary": "Long Beach, California • Berlin, New Jersey",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03527186"
    },
    {
      "nct_id": "NCT02186769",
      "title": "An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Risperdal® Consta®",
          "type": "DRUG"
        },
        {
          "name": "LY03004",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-07",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-06-18",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 2,
      "location_summary": "Orange County, California • Austin, Texas",
      "locations": [
        {
          "city": "Orange County",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186769"
    },
    {
      "nct_id": "NCT00034801",
      "title": "Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression",
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 378,
      "start_date": "2001-09",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2006-07-19",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 30,
      "location_summary": "Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034801"
    },
    {
      "nct_id": "NCT00183612",
      "title": "Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 68,
      "start_date": "2000-05",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2014-01-08",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 2,
      "location_summary": "Belmont, Massachusetts • Medford, Massachusetts",
      "locations": [
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "Medford",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00183612"
    },
    {
      "nct_id": "NCT07483294",
      "title": "Cerebellum-based Imaging Neural Markers for Antipsychotic Response",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychosis; Acute"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 120,
      "start_date": "2025-11-01",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07483294"
    },
    {
      "nct_id": "NCT04404712",
      "title": "FAAH Availability in Psychiatric Disorders: A PET Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder",
        "Alcohol Use Disorder",
        "Psychosis"
      ],
      "interventions": [
        {
          "name": "[11C]MK-3168",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2020-09-23",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404712"
    },
    {
      "nct_id": "NCT01488929",
      "title": "Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Negative Symptoms",
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "TC-5619",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Targacept Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 603,
      "start_date": "2011-12",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 22,
      "location_summary": "Garden Grove, California • Glendale, California • Long Beach, California + 19 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01488929"
    },
    {
      "nct_id": "NCT00435370",
      "title": "Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoking Cessation",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Tropisetron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 179,
      "start_date": "2006-11",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00435370"
    },
    {
      "nct_id": "NCT00097942",
      "title": "Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "memantine HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 138,
      "start_date": "2004-08",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2012-03-05",
      "last_synced_at": "2026-10-11T11:30:20.156Z",
      "location_count": 13,
      "location_summary": "National City, California • San Diego, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097942"
    }
  ]
}